trending Market Intelligence /marketintelligence/en/news-insights/trending/mthrIQhtp1m9Kwa5rJwt2g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Grifols sells 2 businesses to shareholder Scranton Enterprises for $537M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Grifols sells 2 businesses to shareholder Scranton Enterprises for $537M

Spanish biotechnology company Grifols SA said it sold two businesses it acquired earlier this year to its existing shareholder Scranton Enterprises BV.

Scranton will pay $537 million for the businesses, effectively the same price Grifols paid when it acquired Haema AG for €220 million in June and Biotest US Corp. for $286 million in August.

Biotest and Haema will continue to provide plasma to Grifols under a supply agreement that has been extended to a 30-year period. Grifols also has the ability to repurchase the businesses.